Predict your next investment

Venture Capital
biocrossroads.com

See what CB Insights has to offer

Investments

30

Portfolio Exits

3

Funds

3

About BioCrossroads

BioCrossroads is Indiana's initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region's existing research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises (Indiana Health Information Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, and Datalys Center), expands collaboration and partnerships among Indiana's life science institutions, promotes science education and markets Indiana's life sciences industry.

BioCrossroads Headquarter Location

300 North Meridian Street

Indianapolis, Indiana, 46204-1753,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioCrossroads

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find BioCrossroads in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest BioCrossroads News

Inotiv Founder Named Watanabe Award Winner

Oct 13, 2021

The board of directors for BioCrossroads has named Dr. Peter Kissinger, founder of West Lafayette-based Inotiv Inc. (Nasdaq: NOTV), the recipient of the 2021 August M. Watanabe Life Sciences Champion of the Year Award. Kissinger also spent more than...

BioCrossroads Investments

30 Investments

BioCrossroads has made 30 investments. Their latest investment was in Novosteo as part of their Series A on January 1, 2021.

CBI Logo

BioCrossroads Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/14/2021

Series A

Novosteo

$5.5M

Yes

2

7/27/2020

Series A

MBX Biosciences

$34.6M

No

5

9/24/2019

Series A

Sexton Biotechnologies

$5M

Yes

6

6/12/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/10/2019

Debt

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/14/2021

7/27/2020

9/24/2019

6/12/2019

5/10/2019

Round

Series A

Series A

Series A

Series A

Debt

Company

Novosteo

MBX Biosciences

Sexton Biotechnologies

Subscribe to see more

Subscribe to see more

Amount

$5.5M

$34.6M

$5M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

5

6

10

10

BioCrossroads Portfolio Exits

3 Portfolio Exits

BioCrossroads has 3 portfolio exits. Their latest portfolio exit was Sexton Biotechnologies on August 09, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/9/2021

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/9/2021

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

10

BioCrossroads Fund History

3 Fund Histories

BioCrossroads has 3 funds, including Indiana Seed Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/11/2018

Indiana Seed Fund III

Early-Stage Venture Capital

$9M

3

6/5/2012

Indiana Seed Fund II

Subscribe to see more

$99M

10

6/6/2005

Indiana Seed Fund I

Subscribe to see more

$99M

10

Closing Date

10/11/2018

6/5/2012

6/6/2005

Fund

Indiana Seed Fund III

Indiana Seed Fund II

Indiana Seed Fund I

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$9M

$99M

$99M

Sources

3

10

10

BioCrossroads Team

3 Team Members

BioCrossroads has 3 team members, including current Chief Executive Officer, David Johnson.

Name

Work History

Title

Status

David Johnson

Chief Executive Officer

Current

Patricia Martin

Chief Executive Officer

Current

Charles E. Schalliol

Eli Lilly and Company, and Lilly Ventures

President

Former

Name

David Johnson

Patricia Martin

Charles E. Schalliol

Work History

Eli Lilly and Company, and Lilly Ventures

Title

Chief Executive Officer

Chief Executive Officer

President

Status

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.